放射性药物公司ABX收购TRIMT-动脉网

ABX acquires biotech start-up TRIMT

D-Pharm 等信源发布 2026-09-10 12:00



可切换为仅中文







ABX announced the acquisition of TRIMT GmbH, a biotechnology company developing

ABX 宣布收购正在开发生物技术的 TRIMT GmbH

radiopharmaceuticals

放射性药物

targeting the

针对

integrins

整合素

αvβ6 and αvβ8. The acquisition expands ABX’s precision-

αvβ6和αvβ8。此次收购扩大了ABX的精准

oncology

肿瘤学

pipeline with a proprietary integrin targeted radiopharmaceutical platform and brings together TRIMT’s scientific innovation in cyclopeptide ligands with ABX’s end-to-end capabilities in radiopharmaceutical development, clinical manufacturing, regulatory support, commercialization and global supply..

拥有专有的整合素靶向放射性药物平台，并将TRIMT在环肽配体方面的科学创新与ABX在放射性药物开发、临床生产、监管支持、商业化及全球供应方面的端到端能力相结合。

TRIMT has a proprietary portfolio of cyclopeptide-based compounds, including the αvβ6-integrin targeted PET imaging agent ⁶⁸Ga-Trivehexin and the therapeutic candidate ¹⁷⁷Lu-Therahexin, as well as the αvβ8-integrin targeted PET imaging agent ⁶⁸Ga-Triveoctin. All three compounds are investigational and have not been approved for commercial use..

TRIMT 拥有一个专有的环肽类化合物组合，包括靶向 αvβ6 整合素的 PET 显像剂 ⁶⁸Ga-Trivehexin 和治疗候选药物 ¹⁷⁷Lu-Therahexin，以及靶向 αvβ8 整合素的 PET 显像剂 ⁶⁸Ga-Triveoctin。这三种化合物均处于研究阶段，尚未获批用于商业用途。

The integrins αvβ6 and αvβ8 are cell-surface receptors that are expressed at low levels in many healthy adult tissues but can be upregulated in cancer and other diseases. This makes them attractive targets for molecular imaging and targeted radionuclide therapy.

整合素αvβ6和αvβ8是细胞表面受体，在许多健康成人组织中表达水平较低，但在癌症和其他疾病中可能上调。这使得它们成为分子成像和靶向放射性核素治疗的有吸引力的靶点。

One of the largest private investment rounds in European biotech to-date

迄今为止欧洲生物技术领域规模最大的私人投资轮次之一

ITM Announces €255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities

ITM 宣布完成2.55亿欧元融资，计划推进放射性药物管线并扩大放射性同位素生产能力

Read news

阅读新闻

Clinical and translational research has demonstrated the potential to visualize integrin expression across a range of epithelial malignancies. ⁶⁸Ga- Trivehexin, ¹⁷⁷Lu-Therahexin, and⁶⁸Ga-Triveoctin are currently under clinical investigation, and their safety and efficacy have not been established.

临床和转化研究已证实，可视化多种上皮性恶性肿瘤中整合素表达具有潜力。⁶⁸Ga-Trivehexin、¹⁷⁷Lu-Therahexin 和 ⁶⁸Ga-Triveoctin 目前正处于临床研究阶段，其安全性和有效性尚未确立。

The acquisition provides ABX with the rights to develop and commercialize TRIMT's proprietary intellectual property, cyclopeptide technology platform, and clinical-stage development portfolio, creating the opportunity to further advance both diagnostic and therapeutic applications within the rapidly growing theranostics landscape..

此次收购使ABX获得开发及商业化TRIMT专有知识产权、环肽技术平台以及临床阶段产品组合的权利，从而在快速发展的诊疗一体化领域中，为进一步推进诊断和治疗应用创造机遇。

“The acquisition of TRIMT and its integrin-targeted platform marks an important step in the expansion of ABX’s oncology portfolio,” said Dr. Marco Müller, CEO of ABX. “Trivehexin, Therahexin and Triveoctin provide us with an exciting scientific and clinical foundation. By combining TRIMT’s expertise in integrin biology with ABX’s clinical development, manufacturing and global supply capabilities, we aim to advance these programs efficiently and responsibly.

“收购TRIMT及其整合素靶向平台，标志着ABX肿瘤产品组合扩展的重要一步。”ABX首席执行官Marco Müller博士表示，“Trivehexin、Therahexin和Triveoctin为我们提供了令人振奋的科学与临床基础。通过将TRIMT在整合素生物学领域的专业知识与ABX的临床开发、生产及全球供应能力相结合，我们旨在高效且负责任地推进这些项目。”

We aim to create new options for patients with cancers that remain difficult to diagnose and treat.”.

“我们旨在为那些仍然难以诊断和治疗的癌症患者创造新的选择。”

ABX will build on its 30 years of experience across the radiopharmaceutical value chain - from early research and development to clinical manufacturing, regulatory support, commercialization and worldwide supply - to support ongoing and future clinical programs for the acquired portfolio. ABX’s track record includes contributing to the development of the prostate cancer therapeutic ¹⁷⁷Lu-PSMA-617 through Phase II before sublicensing the program to Endocyte, now part of Novartis.

ABX将凭借其在放射性药物价值链上30年的经验——涵盖从早期研发到临床生产、监管支持、商业化及全球供应——为已收购产品组合的现有及未来临床项目提供支持。ABX的业绩记录包括推动前列腺癌治疗药物¹⁷⁷Lu-PSMA-617完成II期临床试验开发，随后将该项目分许可给Endocyte（现为诺华旗下公司）。

The company also developed the prostate cancer imaging agent ¹⁸F-PSMA-1007 , which is approved in selected countries across Europe, Asia and North Africa..

该公司还开发了前列腺癌成像剂¹⁸F-PSMA-1007，该药剂已在欧洲、亚洲和北非的部分国家获得批准。

“When we founded TRIMT, our vision was to translate an outstanding class of integrin binding molecules biology into radiopharmaceuticals that could make a meaningful difference for cancer patients,” said TRIMT founders Dr. Jakub Simecek, Dr. Johannes Notni and Dr. Dirk Freitag-Stechl in a joint statement.

TRIMT创始人Jakub Simecek博士、Johannes Notni博士和Dirk Freitag-Stechl博士在一份联合声明中表示：“在创立TRIMT时，我们的愿景是将一类卓越的整合素结合分子生物学成果转化为放射性药物，为癌症患者带来具有临床意义的改善。”

“Together with our exceptional scientific team, we have developed this vision into a leading integrin-targeting platform. In ABX, we have found the right partner to advance its clinical development and work toward bringing these innovations to patients worldwide.”.

“与我们卓越的科研团队携手，我们将这一愿景打造为领先的整合素靶向平台。在ABX，我们找到了合适的合作伙伴，以推进其临床开发，并致力于将这些创新成果带给全球患者。”

The acquisition reinforces ABX’s commitment to precision oncology, molecular imaging, and targeted radionuclide therapy while establishing a strong foundation for the next generatio nof integrin-targeted radiopharmaceuticals.

此次收购强化了ABX在精准肿瘤学、分子成像和靶向放射性核素治疗领域的承诺，同时为下一代整合素靶向放射性药物奠定了坚实基础。

https://www.bionity.com/en/news/1189777/abx-acquires-biotech-start-up-trimt.html

A better way to diagnose and manage neuroendocrine tumors

诊断和管理神经内分泌肿瘤的更好方法

Read news

阅读新闻